Anticoagulation With Rivaroxaban in Post Cardioversion Patients

Trial Profile

Anticoagulation With Rivaroxaban in Post Cardioversion Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Feb 2015

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARC
  • Most Recent Events

    • 25 Oct 2013 Planned End Date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
    • 14 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top